Proactive Investors - Run By Investors For Investors

Scancell rounds up a busy six months

The update was provided as Scancell served up its financial results for the six months ended October 31.
Scancell rounds up a busy six months
Scancell's technology uses the body's immune system to tackle cancer

Scancell Holdings Plc (LON:SCLP) has confirmed it will kick off a phase II clinical trial of its potentially breakthrough cancer treatment in the second half.

SCIB1, which has produced remarkable survival data treating melanoma patients in an early-stage trial, will be administered in combination with another new breed of drug called a checkpoint inhibitor.

Checkpoint inhibitors lower or break cancer’s defence against the body’s immune system, while SCIB1 uses the body’s immune system against the disease.

The SCIB1 data was one of the highlights in a busy period for the drug developer.  

On Monday the company revealed it had found a partner to help it with a phase I/II clinical study of SCIB2 for patients with lung cancer.

And Scancell said a third drug, Modi-1, would likely move into first in man clinical studies for breast cancer, ovarian cancer and a rare type of bone cancer called osteosarcoma next year.

The update was provided as Scancell served up its financial results for the six months ended October 31.

As is common with companies at this formative stage of their development, Scancell was lossmaking (to the tune of £1.72mln, up from £1.17mln). At the period-end it had £4.5mln in the bank.

Why Invest In Scancell Holdings Plc? Read More Here

Register here to be notified of future SCLP Company articles
View full SCLP profile View Profile

Scancell Holdings Plc Timeline

Related Articles

Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.
November 21 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
picture of Paris
April 04 2017
Data from the European head and neck trial with lead product NBTXR3 will be presented at the ASCO meeting in June

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use